NDAORALSOLUTION
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
CELEXA (citalopram hydrobromide) by Forest Devices is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). Approved for depression. First approved in 1999.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CELEXA (citalopram hydrobromide) is an oral SSRI approved in 1999 for depression and off-label hot flashes. The mechanism involves inhibition of serotonin reuptake in the central nervous system, though the exact pharmacodynamic basis remains incompletely understood.
$0.003BPart D
LOE ApproachingDeclining
As LOE approaches with minimal current Part D spending ($3M), the brand team is likely contracted and focused on managed transition rather than growth initiatives.
Mechanism of Action
unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Indications (1)
Clinical Trials (2)
Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions
Started Oct 2003
24 enrolled
Healthy
Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
Started Oct 2003
24 enrolled
Healthy
Worked on CELEXA at Forest Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.